Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 6:25 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 925 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: PSORIASIS Clear all

Conditions: Plaque Psoriasis
Interventions: Risankizumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 244 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 20
States / cities: Phoenix, Arizona • Hot Springs, Arkansas • North Little Rock, Arkansas + 16 more

Conditions: Psoriasis
Interventions: NB-UVB Phototherapy; Device
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Pruritus, Psoriasis
Interventions: SNA-120, Placebo, Calcipotriene; Drug
Lead sponsor: Sienna Biopharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 17
States / cities: Anniston, Alabama • Mobile, Alabama • Fountain Valley, California + 14 more

Conditions: Systemic Lupus Erythematosus, Arthritic Psoriasis, Psoriasis, Inflammatory Bowel Diseases
Interventions: BMS-986165 Capsule, BMS-986165 Tablet; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Psoriasis
Interventions: CP-690,550, Placebo Vehicle; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 14
States / cities: Irvine, California • San Diego, California • Chicago, Illinois + 9 more

Conditions: Plaque Psoriasis
Interventions: Roflumilast Cream 0.3%, Roflumilast Cream 0.15%, Vehicle Cream; Drug
Lead sponsor: Arcutis Biotherapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 331 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 20
States / cities: Beverly Hills, California • Northridge, California • San Diego, California + 16 more

Conditions: Plaque Psoriasis
Interventions: DSXS topical; Drug
Lead sponsor: Sun Pharmaceutical Industries, Inc.; Industry
Eligibility: 2 Years to 18 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Hawthorne, New York

Conditions: Psoriatic Arthritis
Interventions: Dose A VTX958, Dose B VTX958, Placebo; Drug
Lead sponsor: Ventyx Biosciences, Inc; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 15
States / cities: Phoenix, Arizona • Newport Beach, California • Clearwater, Florida + 12 more

Conditions: Psoriasis
Interventions: Luma Light System, Luma Light, Occlusive Dressing; Device
Lead sponsor: Illumicure Inc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2015
U.S. locations: 1
States / cities: Santa Rosa, California

Conditions: Plaque Psoriasis
Interventions: Placebo 2 mL auto-injector, Placebo 1 mL prefilled syringe, Secukinumab 2 mL auto-injector, Secukinumab 1 mL prefilled syringe; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 8
States / cities: Miami, Florida • Marietta, Georgia • Saint Joseph, Missouri + 5 more

Conditions: Parapsoriasis
Interventions: Apremilast, Placebo, Placebo-Apremilast; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 221 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 26
States / cities: Birmingham, Alabama • Fremont, California • Los Angeles, California + 21 more

Conditions: Plaque Psoriasis, Skin Diseases
Interventions: JTE-051, Placebo; Drug
Lead sponsor: Shionogi Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 12
States / cities: Fountain Valley, California • Fremont, California • Tampa, Florida + 9 more

Conditions: Psoriasis
Interventions: Collaborative Connected health, (CCH), Control; Other
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 3
States / cities: Los Angeles, California • Sacramento, California • Aurora, Colorado

Conditions: Arthritis, Rheumatoid, Arthritis, Psoriatic, Psoriasis, Ankylosing Spondylitis, Autoimmune Diseases
Interventions: Root-cause autoimmune treatment program; Other
Lead sponsor: AndHealth; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 2,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Arthritis, Psoriatic
Interventions: Icotrokinra, Placebo, Active reference comparator; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 552 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 9
States / cities: Jonesboro, Arkansas • DeBary, Florida • Plantation, Florida + 6 more

Conditions: Psoriasis
Interventions: Fibroscan and Fibrosure; Diagnostic Test
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Psoriasis
Interventions: CTA018 cream; Drug
Lead sponsor: OPKO Health, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 16
States / cities: Tucson, Arizona • Little Rock, Arkansas • Chicago, Illinois + 12 more

Conditions: Atopic Dermatitis, Plaque Psoriasis
Interventions: PF-07038124 ointment 0.01%, Vehicle ointment, PF-07038124 ointment 0.03%, PF-07038124 ointment 0.06%; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years and older
Enrollment: 263 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 23
States / cities: Encinitas, California • Los Angeles, California • Cape Coral, Florida + 17 more

Conditions: Plaque Psoriasis
Interventions: Prurisol, Placebo; Drug
Lead sponsor: Cellceutix Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 9
States / cities: Huntsville, Alabama • Encino, California • Coral Gables, Florida + 5 more

Conditions: Psoriasis
Interventions: Daclizumab, NB-UVB; Drug · Device
Lead sponsor: Rockefeller University; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2008
U.S. locations: 3
States / cities: New York, New York

Conditions: Scalp Psoriasis
Interventions: Roflumilast Foam 0.3%, Vehicle Foam; Drug
Lead sponsor: Arcutis Biotherapeutics, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 432 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 36
States / cities: Scottsdale, Arizona • Beverly Hills, California • Encinitas, California + 31 more

Conditions: Plaque Psoriasis
Interventions: Topicort® (desoximetasone) Topical Spray, 0.25%; Drug
Lead sponsor: Sun Pharmaceutical Industries, Inc.; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Hawthorne, New York

Conditions: Psoriasis
Interventions: Brodalumab, Comparator Drug (non-biologic IL-17 inhibitors); Biological · Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 3,500 participants
Timeline: 2017 – 2031
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Psoriasis, Moderate to Severe
Interventions: BMS 587101; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 16
States / cities: Phoenix, Arizona • Tucson, Arizona • San Diego, California + 13 more

Search by objective public record fields.

A Study of the Safety and Efficacy of Risankizumab in Adult Participants With Plaque Psoriasis Who Have Had a Suboptimal Response to Secukinumab or Ixekizumab

Psoriasis Microbiome and Phototherapy

Safety, Tolerability and Efficacy of SNA-120 for Treatment of Pruritus and Psoriasis in Subjects Treated With Calcipotriene

A Study to Evaluate BMS-986165 Tablet Formulation Relative to BMS-986165 Capsule Formulation and the Effect of a High-Fat/ High-Calorie Meal and Increased Gastric pH on the BMS-986165 Tablet Formulation

Topical CP-690,550 For Chronic Plaque Psoriasis

The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis

An Open Label, Safety Study to Assess the Potential for Adrenal Suppression

VTX958 Versus Placebo for the Treatment of Active Psoriatic Arthritis (Tranquility-PsA)

Luma Light System Proof of Concept Study in Subjects With Mild to Moderate Psoriasis

Study of Efficacy and Safety of Secukinumab 2 mL Auto-injector (300 mg) in Subjects With Moderate to Severe Plaque Psoriasis

A Phase 4 Study of Efficacy and Safety of Apremilast in Subjects With Moderate Plaque Psoriasis.

Study to Evaluate the Safety and Efficacy of JTE-051 in Subjects With Moderate to Severe Plaque Psoriasis

Collaborative Connected Health (CCH) for PCORI

IMPACT - AndHealth Autoimmune Research Registry

A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis

FibroScan ® Study: Assessing Liver Fibrosis in Patients Using Methotrexate for Psoriasis

Safety and Efficacy of Topically Applied CTA018 in Plaque Psoriasis

A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis.

Efficacy and Safety of Prurisol Administered Orally for Active Mild to Moderate Chronic Plaque Psoriasis

To Study the Use of Humanized CD25 in Preventing the Relapse of Psoriasis Vulgaris

Topical Roflumilast to Treat Scalp and Body Psoriasis (ARRECTOR)

Adrenal Suppression and Pharmacokinetics of Topicort® Spray, 0.25% in Pediatric Patients With Plaque Psoriasis

LTS of Siliq vs. Other Therapies Treating of Adults With Moderate-to-Severe Psoriasis

Study of BMS-587101 in Patients With Moderate to Severe Psoriasis